Hi, I'm Chris Thompson from Investor Intel and today I'm speaking with David Regan, the CEO of Sonat Nanotech. S-O-N-A is the ticker symbol on the Canadian Security Exchange. How are you today, David? I'm great Chris. Thanks for having me on. Your company is a nanotechnology life sciences company, maybe for investors who may not know much about what that is. Can you give us a brief background on it? Sure. So Sonat Nanotech is a company that's been built up around its proprietary and patent pending gold nanorod technology. And really what that is is the technology that enables us to manipulate particles of gold on the nanoscale uniquely without the use of toxins. And that I'll tell you a little bit further on, but why that's important. But we've built the company up and we've got two focuses leveraging on that technology. Okay, and so what are the focuses that the technology is used for? So the gold nanorods can be used in a variety of different applications. We've built up an expertise in lateral flow rapid tests. So the ones like pregnancy tests and of course the COVID that we've all seen oh so many times in the past year and a half sadly. The second area is a longer term focus for us in terms of researching out the capabilities of our particular technology that we're able to be used in the body for such things as photo thermal applications and targeted drug delivery. Okay, so how are you testing these applications? Are you working with various universities? I saw there was a recent announcement with U of T maybe you can go into that of it. Yeah, we're very fortunate to be working with Dr. Warren Chan at the leading bioengineering institute in Canada and their lab. And we're very excited. And what we'll be exploring in the studies that will be announced in future we expect is the bio compatibility of our gold nanorods. Again, going back to this idea that we uniquely can make gold nanorods without the use of toxins and that of course can imagine Chris is going to be extremely important when we start taking these tiny gold nanorods and putting them in the body for various medical applications. Now I've got to say this is an emerging area of science and medicine and it is many years from fully being developed and it will rely upon researchers and entrepreneurs from around the world but we believe we can play a very important role in that. And what are the sort of the major diagnostic tests that you would be using the gold nanorods with? So there are a variety of different rapid tests we're working on right now. A concussion test importantly rapid concussion test doesn't exist that can be used within a number of minutes field side. We're working on of course a COVID test and we have a COVID test that uses saliva that we're very excited about. We partnered with a great company in the US that's already FDA certified called Arlington Scientific and to date there's no rapid saliva test that's been approved. We think that's one that can make can play a very very important role in limiting the pandemic. Well just follow this train of thought for a second with the COVID test and that relationship will that sort of bring review into the companies sort of in the next year or so? Well it's interesting because we talk about the two different areas of focus the company has right now. The first one on diagnostics that's that we expect much near term revenues to a crew from there particularly our COVID saliva test which is in the midst of an IRB approval in the US and we expect to kick off a clinical study for it in the coming weeks. And now what is your background with the company? So I've been with the company for about a year and a half. It's been a very exciting time for the company. The company was in a startup phase at the time and the company has grown a fair amount and has learned a great deal in the last year and a half. It's been exciting times and and we're very pleased at this stage with the the developments both on the longer term research prospects for our gold nanorod technology as well as the near term revenues associated with for what we expect to be revenues associated with an an antigen test for saliva in the US in the coming months. So as investors looking at your company to make an investment in on the biotech space what can they expect from the new flow say for the next six months or so into 2022? Well Chris we've got a number of things going on on both fronts. First on the on the fundamental research side which is we believe the bigger opportunity frankly but much much more longer term because of those medical applications and the work that needs to be done by by many around the world but nonetheless with an MOU with the University of Toronto's Bioengineering Institute announced we hope to have more to discuss around that as far as some of the specific studies that we think can be quite exciting because we expect to be able to prove out the bio compatibility of our gold nanorods. On the other side of the company on the rapid diagnostics front we've already announced that we've we are anticipating a clinical trial for our saliva test in the US with the US partner who is FDA certified and has a great deal of experience working with the FDA and has extremely strong distribution in the US so we think there'll be a number of different developments to be speaking about in the coming months if all goes well. Well great we look forward to following your company and interviewing you again soon when you have some additional news and I appreciate your time today I was speaking with David Regan who is the CEO of Sohn on the Tech ticker symbol is SONA on the CSE thanks very time David. Thanks Chris look forward to catching up next time.